KRAS mutational status affects oxaliplatin-based chemotherapy independently from basal mRNA ERCC-1 expression in metastatic colorectal cancer patients

BACKGROUND: In this study, we evaluated the possibility that KRAS mutational status might be predictive of oxaliplatin (OXA) efficacy. We also explored the role of excision repair cross complementing group-1 (ERCC-1). METHODS: Ninety anti-epidermal growth factor receptor-naive advanced colorectal ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Basso, M, Strippoli, A, Orlandi, A, Martini, M, Calegari, M A, Schinzari, G, Di Salvatore, M, Cenci, T, Cassano, A, Larocca, L M, Barone, C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Molecular Diagnostics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3553525/
https://www.ncbi.nlm.nih.gov/pubmed/23175150
http://dx.doi.org/10.1038/bjc.2012.526

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3553525/
https://www.ncbi.nlm.nih.gov/pubmed/23175150
http://dx.doi.org/10.1038/bjc.2012.526

Ejemplares similares